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estimate the burden of illness in PAH patients. Methods: Data came from a large 
commercial claims database. PAH patients were identified based on having > 2 medi-
cal claims for primary pulmonary hypertension (ICD-9 code:416.0), and either one 
claim for right heart catheterization or one claim of echocardiogram and diagnosed 
by a pulmonologist/cardiologist within 12 months of the medical claim. The first 
medical claim during this period served as in the index date with 12 months prior 
to this event as baseline and 12 months post as follow-up period. Demographic 
variables were extracted at a patient level from administrative files and economic 
variables, which included health care utilization and costs for outpatient, inpatient, 
emergency and pharmacy services came from the respective medical and pharmacy 
claim files and summarized at a per-patient-per-month (PPPM). Five controls were 
randomly picked and matched to each PAH patient on demographic characteristics. 
Incremental burden of PAH was estimated using non-parametric statistical tests 
between controls and PAH group. All costs were adjusted to 2012 base year using 
consumer price index. Results: A total of 2,245 PAH patients were identified and 
matched to 11,225 controls. PAH group had significantly higher (p< 0.001) PPPM 
health care utilization compared to the matched control across all drivers: outpa-
tient (2.6 vs. 1.5), inpatient (0.08 vs. 0.02), emergency room (0.1 vs. 0.04), and phar-
macy services (4.2 vs. 2.6). The increase in utilization translated in higher (p< 0.001) 
total PPPM incremental costs of $3,193 in the PAH group with inpatient ($1,665 
vs. $345) and pharmacy costs ($790 vs. $178) being as much as five times greater 
compared to controls. ConClusions: Health care resource use and costs for PAH 
patients is high from a managed care perspective.
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objeCtives: To describe the incidence and profile of patients hospitalised for acute 
heart failure (AHF); to assess the trajectories of patients before and after hospitaliza-
tion; and to estimate the cost of AHF inpatients stays. Methods: Patients with AHF 
were identified over a 5-year period (2006 - 2010) from the French PMSI (Programme 
de Médicalisation des Systèmes d’Information), a national disease-related group 
inpatient database. The PMSI database contains data related to all private and public 
hospital stays in France (about 20 millions/year). Heart failure was identified with 
the ICD-10, code I50. Results: The numbers of patients hospitalised at least once 
per year for AHF increased from 144,043 in 2006 to 158,623 in 2010. These num-
bers lead to incidence rates of 2.28‰ in 2006 and 2.45‰ in 2010. The proportion of 
patients aged ≥ 75 increased from 71.0% in 2006 to 74.3% in 2010. Half of patients 
were male. The mean number of comorbidities was 9.6 in 2010. The mean length of 
stay was 9.5 days and 12.6 days per year (2010), as mean re-hospitalization for AHF 
within the same year was 22%. The mean annual number of AHF hospitalisations 
per patient was 1.3. The mean cost for an AHF hospitalisation in the acute setting 
was 4,713€ in 2010. The mean annual cost for all hospitalisations occurring for a 
patient hospitalised at least once in a year (2010) for AHF was 6,253€ . Mean costs 
per hospital stay was higher if the patient died during hospitalisation (5,722€ vs. 
4,627€ , p< 0.001). Extrapolation to the whole country leads to a yearly cost of nearly 
a billion of euros (991 millions). ConClusions: Incidence of AHF hospitalisation 
increased in the recent years. This analysis highlighted the high economic hospital 
burden of AHF in France.
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objeCtives: Stroke has catastrophic consequences resulting in death or disability 
in 80% of patients and representing a substantial burden on the health care system, 
as well as on patients, family, and society. Stroke is considered as the 2ndcause of 
burden of disease in Europe and ischemic stroke (IS) represents a high percent-
age of total strokes. The objective of the present study was to analyze the first 
year post-stroke burden of IS in Spain. Methods: We performed an observational, 
multicenter, naturalistic and prospective study that included 16 hospitals (stroke 
units of National Health System hospitals) of 16 Spain regions. We took into con-
sideration consumption of health care resources, social burden, productivity lost 
and health-related quality of live of patient and caregiver during the first year 
post-stroke. Results: A total of 321 stroke patients were recruited. Mean age 72 
years, 54.8% male. Basal NIH stroke scale was 9.11 and 28.9% presented moderate-
high disability. 291 (90.7%) patients presented IS. Overall 1-year cost per IS was 
27,596.53€ . Direct health care costs were 8,623.35€ (31.25%), direct intrahospital 
health care costs supposed 69% (5,926.21€ ) of these costs. Direct non-health care 
costs were 18,377.75€ (66.59%), of which 16,515.09€ (59.84%) were informal care 
costs. Productivity lost was 595.43€ (2.16%). ConClusions: IS were the majority 
of total strokes in the study and represent a high burden on health care system and 
society, mainly due to hospitalization and informal care costs. Intrahospital costs 
were double than the published DRGs in Spain. Other diseases like Alzheimer or 
dementia represent a lower burden than stroke.
PCV59
follow-on HeAltH CAre Costs in PAtients witH ACute CoronArY 
sYnDrome (ACs)
Berger A.1, LaPensee K.2, Oster G.1
1Policy Analysis Inc. (PAI), Brookline, MA, USA, 2The Medicines Company, Parsippany, NJ, USA
objeCtives: To review published estimates of post-acute-care costs over one year 
in patients with acute coronary syndrome (ACS). Methods: Using the Medline and 
in EU5, a subject about which nothing has been published to date. Methods: A 
burden of illness model was constructed to examine the impact of RHT in EU5, 
specifically the incremental incidence, mortality and direct medical costs of CVD, 
which includes: coronary heart disease (CHD), congestive heart failure (CHF) and 
stroke. Framingham risk equations which included a coefficient for treatment resist-
ance and SCORE risk charts were used to estimate the risk of CVD for patients 
with and without RHT. Transition probability data were taken from the literature 
to estimate the risk of death from CVD events, subsequent CVD events and ESRD. 
Direct costs for these events and their long-term consequences were taken from 
the literature and from country-specific drug and acute inpatient costs. Results: 
The total direct medical cost of RHT in EU5 is estimated to be € 3.9 billion in 2013. 
This does not include the cost for drugs to treat RHT, or other costs such as lost 
productivity not directly borne by the health care system. RHT will contribute to 
188,000 cases of CHD, 57,400 strokes, 31,500 CHF and 1,400 ESRD and 30,000 deaths 
in 2013. ConClusions: The burden of RHT due to the increased incidence of CVD 
and ESRD is high. Reducing the incidence of CVD and ESRD through better blood 
pressure control should be a priority for health care decision makers.
PCV54
retrosPeCtiVe Costing stuDY to estimAte BurDen of HeArt fAilure 
in sPAin
Llorens P.1, Crespo C.2, Pérez-Alcántara F.2
1Hospital General Universitario, Alicante, Spain, 2Oblikue Consulting, Barcelona, Spain
objeCtives: To analyze and estimate resource utilization and associated costs, 
one year following an acute episode of heart failure (HF) in Spain. Methods: 
Patient-flow data after index hospitalization for acute HF (AHF) were obtained 
from EAHFE database, an emergency (ER)-based registry containing records of all 
AHF patients treated in 29 Spanish hospitals (over 5,800 cases). Estimated medical 
resource utilization data during patients’ ER and other wards stay, hospitalization, 
and first-year follow-up was collected from medical specialists through question-
naire. AHF episodes and hospitalizations incident rates were estimated through 
literature review and disease statistics in official sources. Cost data was retrieved 
from Spanish Pharmacists official sources and a national health care costs database 
(Euros, 2013). To assess uncertainty, sensitivity analysis was carried out. Results: 
A total of 111,803 annual hospital admissions are estimated in Spain (2013). 92% 
of patients suffering an AHF episode are discharged alive and of these 90% survive 
the first month; 23% of these patients are discharged directly from ER, while the 
majority of those who are hospitalized, are admitted to Internal Medicine (53%) or 
Cardiology (17%) wards. On an average, patients are re-admitted 0.41 times within 1 
year. Total direct costs in the first year following an AHF episode averages € 6,822, of 
which 88% are incurred in hospital, with drugs and diagnostic tests accounting for 
less than 5% of all hospital costs. Follow-up costs, in average, split equally between 
drugs and outpatient visits/tests, but vary widely depending on local HF protocols. 
Extrapolation of results to the Spanish population suggests that the total burden of 
HF is more than € 542 million per year. ConClusions: Treating HF patients within 
Spain is resource intensive. Costs are primarily incurred in hospital and are mostly 
driven by the length of stay.
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objeCtives: Chronic thromboembolic hypertension (CTEPH) is associated with 
considerable morbidity and mortality. The objective of this study was to describe the 
burden of illness in patients with CTEPH. Methods: Data for this study came from 
a large commercial claims database. CTEPH patients were identified based on having 
> 2 medical claims for either primary pulmonary hypertension (ICD-9 code:416.0) or 
chronic pulmonary heart disease (ICD-9 code:416.8), history of pulmonary embolism 
in the past one year (ICD-9 code:415.1, V12.51, 38.7; CPT-4 codes:36010, 37620, 75825, 
75940; HCPCS codes:C1880) and either one claim for right heart catheterization 
or one claim of echocardiogram and diagnosed by a pulmonologist/cardiologist 
within 12 months of the medical claim. Demographic variables were extracted at 
a patient level from administrative files and economic variables, which included 
health care utilization and costs for outpatient, inpatient, emergency and pharmacy 
services came from the respective medical and pharmacy claim files and sum-
marized at a per-patient-per-month (PPPM). Five controls were randomly picked 
and matched to each CTEPH patient on demographic characteristics. Incremental 
burden of CTEPH was estimated using non-parametric statistical tests between 
controls and CTEPH group. All costs were adjusted to 2012 base year using consumer 
price index. Results: A total of 191 CTEPH patients were identified and matched 
to 955 controls. CTEPH group had significantly higher (p< 0.001) PPPM health care 
utilization compared to the matched control across all drivers: outpatient (3.1 vs. 
1.5), inpatient (0.13 vs. 0.02), emergency room (0.16 vs. 0.04), and pharmacy services 
(4.5 vs. 2.6). The increase in utilization translated in higher (p< 0.001) total PPPM 
incremental costs of $5,007 in the CTEPH group with inpatient ($3,909 vs. $332) and 
pharmacy costs ($607 vs. $180) being as much as twelve and three times greater 
compared to controls. ConClusions: Health care resource use and costs for CTEPH 
patients is high from a managed care perspective.
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objeCtives: Pulmonary arterial hypertension (PAH) is a progressive disease result-
ing in high health care resource use and costs. The objective of this study was to 
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objeCtives: To compare the economic burden and health care utilizations of U.S. 
veteran patients diagnosed with hypertension. Methods: A retrospective database 
analysis was performed using the Veterans Health Administration Medical SAS 
datasets from October 1, 2008 to September 30, 2012. Patients diagnosed with hyper-
tension were identified using International Classification of Disease 9th Revision 
Clinical Modification (ICD-9-CM) diagnosis codes 401.x, 402.xx, 403.xx, and 404.
xx, with the first diagnosis date designated as the index date. A comparison group 
of patients without hypertension but of the same age, region, gender and index 
year were identified and matched by baseline Charlson Comorbidity Index. The 
index date for the comparator group was randomly chosen to reduce selection bias. 
Patients in both groups were required to be at least 18 years old, and have continu-
ous medical and pharmacy benefits 1 year pre- and 1 year post-index date. Study 
outcomes, including health care costs and utilizations, were compared between 
the disease and comparator groups using 1:1 propensity score matching. Results: 
A total of 2,422,810 patients were included in the hypertension and comparison 
cohorts. After 1:1 matching, a total of 748,857 patients were matched from each 
group, and baseline characteristics were well-balanced. Patients diagnosed with 
hypertension utilized more health care resources for inpatient (8.21% vs. 1.01%, 
p< 0.01), emergency room (ER) (12.78% vs. 3.60%, p< 0.01), physician office (99.43% 
vs. 39.45%, p< 0.01), outpatient visits (99.61% vs. 40.14%, p< 0.01), and pharmacy 
visits (85.51% vs. 35.66%, p< 0.01). The disease group also had higher patient expen-
ditures for inpatient ($2,568 vs. $289, p< 0.01), ER ($121 vs. $30, p< 0.01), physician 
office ($2,541 vs. $767, p< 0.01), outpatient visit ($2,844 vs. $853) and pharmacy visits 
($544 vs. $191, p< 0.01) than the comparison group. ConClusions: Results suggest 
that patients diagnosed with hypertension incurred significantly higher health care 
utilizations and costs compared to those without.
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objeCtives: Surgical aortic valve replacement (sAVR) represents the gold stand-
ard for treatment in patients who require valve replacement therapy. However, 
the risks and costs are not uniform across all patients. We have examined the 
national hospital costs database of France to detail the variability of outcomes 
and costs in an attempt to allow improved decision making when deciding on 
appropriate interventions. Methods: The Programme de Médicalisation des 
Systèmes d’Information (PMSI) hospital database for 2010 was examined and all 
discharge records retrieved for patients undergoing aortic valve replacement. In 
addition to the discharge costs information on hospital length of stay, mortality 
and Charlson risk score were also obtained. Results: The mean cost for all 12,512 
recorded sAVR procedures (defined as Groupe homogène de maladies (GHM) codes 
05C02 and 05C03) in 2010 was € 19,029 (median € 17,349). Overall hospital mortal-
ity was 5.94% but increased to 26.06% depending on severity level and GHM code. 
Corresponding total costs increased if patients died prior to discharge by € 11,007 
and € 9,200 for 05C02 and 05C03 respectively but also differed by severity, generally 
increasing together with mortality up to a maximum mean of € 42,063. Hospital 
length of stay (LoS) also varied by severity levels with means of between 10.74 
and 27.91 days dependent on severity. ConClusions: The costs and outcomes of 
sAVR vary enormously and a single point estimate cannot be used to adequately 
to reflect them. Therapeutic choices must be tailored to the individual patient and 
has the potential to generate substantial cost reductions for the payer by avoid-
ing mortality and reducing LoS. We present this in the context of new treatment 
options for aortic valve replacement.
PCV64
eConomiC imPACt of stroke ePisoDe in PAtients PreVious DiAgnoseD 
witH AtriAl fiBrillAtion in PriVAte HeAltH sYstem in BrAzil
Araújo G.1, Santos A.M.2, Preto M.C.3, Bernardino G.D.R.4, Monteiro R.C.4, Fujii R.K.5,  
Donato B.M.K.6, Barbieri D.E.7, Mould J.8, Manfrin D.F.5, Fonseca M.9
1Axia.Bio, Sao Paulo, Brazil, 2Axia.Bio Consulting, São Paulo, Brazil, 3Bristol-Myers Squibb S/A, 
São Paulo, Brazil, 4Bristol-Myers Squibb, São Paulo, Brazil, 5Pfizer, Inc., São Paulo, Brazil, 6Bristol-
Myers Squibb Company, Wallingford, CT, USA, 7Bristol-Myers Squibb – Brazil, São Paulo, Brazil, 
8Pfizer, New York, NY, USA, 9Federal University of São Paulo / Axia.Bio Consulting, São Paulo, 
Brazil
objeCtives: Evaluate the costs of patients with known diagnosis of atrial fibril-
lation who received medical care related to stroke episodes, under the Private 
Healthcare system perspective. Methods: A retrospective evaluation of a data-
base with 3 million individuals was conducted to identify patients diagnosed with 
Atrial Fibrillation (AF) using the International Classification of Diseases version 
10 (ICD10) I48 code (Flutter and atrial fibrillation) between 2009 and 2010. From 
the identified cohort, patients presenting the following codes: ICD10 I64, I63, I66 
and I69, were further analyzed from 2009 to 2012. Costs associated to the episodes 
such as medications, exams, procedures, hospitalizations and others were evalu-
ated. Results: From 1898 patients presenting the AF diagnose identified in the 
database, 66 Presented a diagnosis of stroke. The 66 patients cost BRL 2,325,250.61 
to the supplemental health service, being BRL 2,193,185.50 spent with 21 patients 
hospitalizations due to stroke. ConClusions: If not controlled, AF may impose 
a significant morbidity due to increased susceptibility for thromboembolic events 
such as stroke and its complications, causing important spending beyond hos-
pitalizations and other significant direct and indirect costs to the private health 
care system.
Embase databases, we identified published reports of direct health care costs in ACS 
patients in the US; we limited attention to studies published in English between 
January 1, 2003 and July 30, 2012. Reference lists of all such studies also were scanned 
to identify additional sources. We abstracted information from all relevant reports on 
costs of recurrent events (e.g., myocardial infarction [MI], stroke, ACS-related readmis-
sions) and cardiac procedures, as well as costs of cardiac-related outpatient visits 
and pharmacotherapy and total health care costs, in the year following ACS onset. 
As appropriate, estimates were converted to 2011 US dollars, using the medical-care 
component of the US Consumer Price Index. Results: A total of 16 studies were 
identified that met all selection criteria. For persons with private health insurance 
coverage, estimated cost per recurrent event was lowest for bleeding ($7951) and high-
est for MI (range = $17,081 - $20,348); the cost of ACS-related admissions ranged from 
$6818 to $34,089. For Medicare beneficiaries, cost per recurrent event was lowest for 
other cardiovascular events ($4542 - $14,360) and highest for MI ($10,082 - $11,347); the 
cost of ACS-related admissions was $13,683. Mean total health care costs for patients 
with private insurance coverage ranged from $21,319 to $40,062 in the year following 
ACS onset; similar estimate was identified for Medicare beneficiaries. ConClusions: 
Costs of follow-on care are high in patients with ACS, due to recurrent events, revascu-
larization, and routine follow-on care. In general, costs were higher for patients with 
private health insurance coverage than those with Medicare coverage.
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objeCtives: Few studies have undertaken a global review of major cardiovascular 
conditions and events. This review summarizes the current literature for costs of: 
major cardiovascular diseases/events (angina, myocardial infarction, heart failure, 
stroke/transient ischemic attack, peripheral arterial disease); revascularization 
(coronary, cerebral, or peripheral); coronary heart disease mortality; and cerebro-
vascular mortality. Methods: A systematic search of the scientific literature from 
2007 through 2012 was conducted. English language articles reporting per-patient 
average direct medical costs of any cardiovascular event of interest in any country 
were included. Cost-effectiveness studies and primary prevention interventions 
were excluded. Cost of the event including initial hospitalization (“acute cost”) and 
any re-hospitalizations or post-event follow-up (“follow-up cost”) along with meth-
odologies of each study were abstracted. Results: A total of 176 articles represent-
ing 30 countries were abstracted. Coronary revascularization (N= 46), stroke (N= 43), 
and heart failure (N= 31) articles were heavily represented. Acute cost estimates 
varied widely for all conditions/events (2013 USD): angina ($1,004-8,380); myocar-
dial infarction ($570-$31,321); coronary revascularizations ($240-$129,747); heart 
failure ($536-$28,176); stroke ($577-$167,378); cerebral revascularizations ($7037-
$57,884) peripheral arterial disease ($1241-23,144); peripheral revascularizations 
($2297-$129,865); coronary heart disease inpatient mortality ($7,030-$25,556); cer-
ebrovascular disease inpatient mortality ($6,197-$40,141). Similarly, wide variation 
was found for follow-up cost estimates, based on time horizons that range from 
30-day re-hospitalization to the remainder of life post-initial event. The major-
ity of studies were specific to the United States; for countries other than the US, 
cost estimates for each event were much less robust. Methodological differences 
between articles limit comparability of costs. ConClusions: Though estimates 
vary, the significant economic burden of these cardiovascular events is evident. A 
lack of robust literature in some conditions and countries combined with significant 
heterogeneity of study design and reporting makes comparison of cardiovascular 
event costs difficult. New research should identify a representative sample using 
study designs that allow for comparability.
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objeCtives: Atrial Fibrilation (AF) 5-folds stroke risk, which results in death or dis-
ability in 80% of individuals and the one-year mortality approaches 50%. The objec-
tive of the present study was to determine first year post-stroke costs in patients 
with or without AF. Methods: We performed an observational, multicenter, natu-
ralistic and prospective study that included 16 hospitals (stroke units of National 
Health System hospitals) of 16 Spain regions. We took into consideration all costs 
related to stroke: direct health care costs (inpatient and outpatient), societal cots 
(formal and informal care), and indirect costs (productivity lost) during the first year 
post-stroke. Results: A total of 321 stroke patients were recruited, 291 (90.7%) with 
ischemic stroke (IS) and 30 (9.34%) with intracraneal hemorraghe (ICH); 160 with and 
161 without AF. The mean age was 72±13 years, 54.8% was male, basal NIH stroke 
scale was 9.11±6.79 and 28.9% presented moderate-high disability. The overall cost 
per year was 27,711.10€ . Direct health care costs: 8,491.22€ (30.64%), intrahospital 
costs were 68.8% (5,838.41€ ) of direct health care costs. Direct non-health care costs 
were 18,643.50€ (67.3% of total costs), and informal care supposed 89.5% of these 
costs. Indirect costs were 576.39€ (2.1% of total costs). ICH costs were higher than IS 
costs (28,895.04€ vs 27,596.53€ ). AF costs were higher than non AF but only formal 
care costs were statistically significant. The most explicative variables were age, 
male sex, NIH stroke scale, arterial hypertension comorbidity, and exitus along 
study. ConClusions: Stroke and its consequences represent an important use of 
health care and social resources during first year post-stroke, total costs of stroke 
represent more than 5% of public health care costs in Spain. Several studies from 
other countries showed similar health care costs but lower informal care costs, 
which where more than two-thirds of total costs in our study, with a very high 
burden over the family or informal carer.
